Arcutis Biotherapeutics, ARQT is showing recent insider trading activity. Public SEC records indicate that Life Frazier recently Bought $200,000 worth of shares on 2 months ago. With that said, our editors here at politicsandwallstreet.com, are adding ARQT to our watchlist to see if this momentum continues.
Based on this transaction and a few others from Corporate Insiders of ARQT that Sold 49,584,483 worth of shares in the last 3 months, the Insider Confidence level of Arcutis Biotherapeutics is trending Down.
Since these insiders have unique insights into what's happening at Arcutis Biotherapeutics, this might serve as an indicator of where it is headed.
Here is a list of the latest insider activity for ARQT:
In addition, TradingView issued a sell rating for ARQT over the next month, Barchart.com has a Strong sell rating and Yahoo! Finance has a Neutral short-term outlook.
Uy Ear
Here is a bit more on Arcutis Biotherapeutics, ARQT but please do your own research.
ARQT Summary: Arcutis Biotherapeutics Inc. is late-stage biopharmaceutical company. It is focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases. The company's product pipeline consists of ARQ-151, ARQ-154 and ARQ-252 for multiple indications, including psoriasis, atopic dermatitis, seborrheic dermatitis and eczema, which are in clinical stage. Arcutis Biotherapeutics Inc. is based in Westlake Village, California.
One resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals. Click here for more on Tipranks.com.
This information was sourced from various 3rd party public sources but to get the best insight into insider activity related to ARQT, you should consider joining TipRanks.com.
PoliticsAndWallStreet.com
Disclaimer: Sandpiper Marketing Group, LLC would like to remind you the data contained in this website is not necessarily real-time nor accurate. All stocks, indexes, futures and Forex prices are not provided by exchanges but rather by our editor research at the time of writing this release, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Sandpiper Marketing does not bear any responsibility for any trading losses you might incur as a result of using this data. Sandpiper Marketing Group, LLC or anyone involved with Sandpiper Marketing Group, LLC will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in this website/newsletter is not trustworthy unless verified by their own research. Also, because events/circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
==============================================================================
Based on this transaction and a few others from Corporate Insiders of ARQT that Sold 49,584,483 worth of shares in the last 3 months, the Insider Confidence level of Arcutis Biotherapeutics is trending Down.
Since these insiders have unique insights into what's happening at Arcutis Biotherapeutics, this might serve as an indicator of where it is headed.
Here is a list of the latest insider activity for ARQT:
- Life Frazier - officer: See Remarks, Bought $200,000 worth of shares on 3 days ago
- Patrick Burnett - 10 percent owner, Sold $2,115 worth of shares on 2 months ago
- Patrick Burnett - officer: See Remarks, Sold $9,187 worth of shares on 2 months ago
- Masaru Matsuda - officer: See Remark, Sold $14,278 worth of shares on 4 months ago
In addition, TradingView issued a sell rating for ARQT over the next month, Barchart.com has a Strong sell rating and Yahoo! Finance has a Neutral short-term outlook.
Uy Ear
Here is a bit more on Arcutis Biotherapeutics, ARQT but please do your own research.
ARQT Summary: Arcutis Biotherapeutics Inc. is late-stage biopharmaceutical company. It is focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases. The company's product pipeline consists of ARQ-151, ARQ-154 and ARQ-252 for multiple indications, including psoriasis, atopic dermatitis, seborrheic dermatitis and eczema, which are in clinical stage. Arcutis Biotherapeutics Inc. is based in Westlake Village, California.
- Recent Last Price: $2.34
- Price Change: -$0.04, -1.48%
- Yearly Gain: -85.75%
- Market Cap: $223.14M
- P/E Ratio: -0.419
One resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals. Click here for more on Tipranks.com.
This information was sourced from various 3rd party public sources but to get the best insight into insider activity related to ARQT, you should consider joining TipRanks.com.
PoliticsAndWallStreet.com
Disclaimer: Sandpiper Marketing Group, LLC would like to remind you the data contained in this website is not necessarily real-time nor accurate. All stocks, indexes, futures and Forex prices are not provided by exchanges but rather by our editor research at the time of writing this release, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Sandpiper Marketing does not bear any responsibility for any trading losses you might incur as a result of using this data. Sandpiper Marketing Group, LLC or anyone involved with Sandpiper Marketing Group, LLC will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in this website/newsletter is not trustworthy unless verified by their own research. Also, because events/circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
==============================================================================
